HRP20100372T1 - Farmaceutski sastavi neuroaktivnog steroida i njihova uporaba - Google Patents
Farmaceutski sastavi neuroaktivnog steroida i njihova uporaba Download PDFInfo
- Publication number
- HRP20100372T1 HRP20100372T1 HR20100372T HRP20100372T HRP20100372T1 HR P20100372 T1 HRP20100372 T1 HR P20100372T1 HR 20100372 T HR20100372 T HR 20100372T HR P20100372 T HRP20100372 T HR P20100372T HR P20100372 T1 HRP20100372 T1 HR P20100372T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical composition
- pregnan
- methoxymethyl
- imidazolyl
- hydroxy
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract 11
- 150000003431 steroids Chemical class 0.000 title 1
- 206010036618 Premenstrual syndrome Diseases 0.000 claims abstract 4
- 230000036470 plasma concentration Effects 0.000 claims abstract 4
- 208000007848 Alcoholism Diseases 0.000 claims abstract 3
- 201000007930 alcohol dependence Diseases 0.000 claims abstract 3
- 239000000203 mixture Substances 0.000 claims abstract 3
- 208000020401 Depressive disease Diseases 0.000 claims abstract 2
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 claims abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 2
- 201000000484 premenstrual tension Diseases 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 239000012453 solvate Substances 0.000 claims abstract 2
- 239000008187 granular material Substances 0.000 claims 2
- 239000013563 matrix tablet Substances 0.000 claims 2
- 239000000155 melt Substances 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 230000002969 morbid Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Farmaceutski sastav za uporabu u liječenju depresije, bolesne potrebe za alkoholom i/ili ovisnosti o alkoholu, predmenstrualne napetosti, predmenstrualnog sindroma ili predmenstrualnog disforičnog poremećaja, naznačen time, da sadrži 3α-hidroksi-3 -metoksimetil-21-(1'-imidazolil)-5α-pregnan-20-on ili njegovu farmaceutski prihvatljivu sol ili solvat i jedan ili više farmaceutski prihvatljivih ekscipijenata, kod čega sastav daje stacionarno stanje razine u plazmi 3α-hidroksi-3 -metoksimetil-21-(1'-imidazolil)-5α-pregnan-20-ona u području od 5ng/ml do 500 ng/ml u trajanju od 12 h do 24 h nakon davanja. Patent sadrži još 5 patentnih zahtjeva.
Claims (6)
1. Farmaceutski sastav za uporabu u liječenju depresije, bolesne potrebe za alkoholom i/ili ovisnosti o alkoholu, predmenstrualne napetosti, predmenstrualnog sindroma ili predmenstrualnog disforičnog poremećaja, naznačen time, da sadrži 3α-hidroksi-3β-metoksimetil-21-(1'-imidazolil)-5α-pregnan-20-on ili njegovu farmaceutski prihvatljivu sol ili solvat i jedan ili više farmaceutski prihvatljivih ekscipijenata, kod čega sastav daje stacionarno stanje razine u plazmi 3α-hidroksi-3β-metoksimetil-21-(1'-imidazolil)-5α-pregnan-20-ona u području od 5ng/ml do 500 ng/ml u trajanju od 12 h do 24 h nakon davanja.
2. Farmaceutski sastav za uporabu prema patentnom zahtjevu 1, naznačen time, da daje stacionarno stanje razine u plazmi 3α-hidroksi-3β-metoksimetil-21-(1'-imidazolil)-5α-pregnan-20-ona u području od 50 ng/ml do 500 ng/ml, od 50 ng/ml do 400 ng/ml, od 50 ng/ml do 325 ng/ml, od 50 ng/ml do 100 ng/ml ili od 100 ng/ml do 250 ng/ml.
3. Farmaceutski sastav za uporabu prema patentnom zahtjevu 1, naznačen time, da sastav daje stacionarno stanje razine u plazmi 3α-hidroksi-3β-metoksimetil-21-(1'-imidazolil)-5α-pregnan-20-ona u području od 50 ng/ml do 250 ng/ml.
4. Farmaceutski sastav za uporabu prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, da farmaceutski sastav sadrži od 20 mg do 40 mg, prvenstveno 30 mg 3α-hidroksi-3β-metoksimetil-21-(1'-imidazolil)-5α-pregnan-20-ona.
5. Farmaceutski sastav za uporabu prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, da je farmaceutski sastav prikladan za oralno davanje.
6. Farmaceutski sastav za uporabu prema patentnom zahtjevu 3, naznačen time, da je farmaceutski sastav u obliku hidrofilne matriks tablete, inkapsuliranog iz taline ekstrudiranog multipartikulata, hidrofobne matriks tablete, granulata ekstrudiranog iz taline ili zrnaca za kontrolirano oslobađanje.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68890505P | 2005-06-09 | 2005-06-09 | |
| PCT/EP2006/005574 WO2006131392A1 (en) | 2005-06-09 | 2006-06-09 | Pharmaceutical compositions of a neuroactive steroid and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100372T1 true HRP20100372T1 (hr) | 2010-08-31 |
Family
ID=36790861
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100372T HRP20100372T1 (hr) | 2005-06-09 | 2010-07-02 | Farmaceutski sastavi neuroaktivnog steroida i njihova uporaba |
| HR20120264T HRP20120264T1 (hr) | 2005-06-09 | 2012-03-23 | Farmaceutski sastavi neuroaktivnog steroida i njihove uporabe |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20120264T HRP20120264T1 (hr) | 2005-06-09 | 2012-03-23 | Farmaceutski sastavi neuroaktivnog steroida i njihove uporabe |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US20090131383A1 (hr) |
| EP (3) | EP1888080B1 (hr) |
| JP (2) | JP2008542419A (hr) |
| KR (3) | KR20080017091A (hr) |
| CN (1) | CN101193640A (hr) |
| AT (2) | ATE538797T1 (hr) |
| AU (1) | AU2006256851C1 (hr) |
| BR (1) | BRPI0612921A2 (hr) |
| CA (1) | CA2611430C (hr) |
| CY (2) | CY1110199T1 (hr) |
| DE (1) | DE602006013622D1 (hr) |
| DK (2) | DK1888080T3 (hr) |
| EA (1) | EA013744B1 (hr) |
| ES (2) | ES2344313T3 (hr) |
| HK (2) | HK1118202A1 (hr) |
| HR (2) | HRP20100372T1 (hr) |
| IL (3) | IL187813A (hr) |
| NO (1) | NO20076319L (hr) |
| NZ (1) | NZ562979A (hr) |
| PL (2) | PL2168585T3 (hr) |
| PT (2) | PT2168585E (hr) |
| RS (2) | RS52199B (hr) |
| SI (2) | SI2168585T1 (hr) |
| UA (1) | UA94909C2 (hr) |
| WO (1) | WO2006131392A1 (hr) |
| ZA (1) | ZA200709188B (hr) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2852057C (en) | 2011-10-14 | 2022-06-07 | Sage Therapeutics, Inc. | 3,3-disubstituted 19-nor pregnane compounds, compositions, and uses thereof for the treatment of cns related disorders |
| LT2986624T (lt) | 2013-04-17 | 2020-07-10 | Sage Therapeutics, Inc. | Neuroaktyvūs 9-nor steroidai, skirti gydymo metodams |
| US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
| US20160068563A1 (en) | 2013-04-17 | 2016-03-10 | Boyd L. Harrison | 19-nor neuroactive steroids and methods of use thereof |
| SG10201802389SA (en) | 2013-04-17 | 2018-04-27 | Sage Therapeutics Inc | 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof |
| AU2014290400B2 (en) | 2013-07-19 | 2019-12-05 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| PT3035940T (pt) | 2013-08-23 | 2019-01-28 | Sage Therapeutics Inc | Esteroides neuroativos, composições e seus usos |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| EP3753927B1 (en) | 2014-10-16 | 2023-07-19 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| KR102612943B1 (ko) * | 2014-10-16 | 2023-12-13 | 세이지 테라퓨틱스, 인크. | Cns 장애의 치료를 위한 조성물 및 방법 |
| PT3224269T (pt) | 2014-11-27 | 2020-06-01 | Sage Therapeutics Inc | Composições e métodos para tratamento de distúrbios do snc |
| SI3250210T1 (sl) | 2015-01-26 | 2021-07-30 | Sage Therapeutics, Inc. | Sestavki in metode za zdravljenje CNS motenj |
| US10329320B2 (en) | 2015-02-20 | 2019-06-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| EP4302764A2 (en) | 2016-07-11 | 2024-01-10 | Sage Therapeutics, Inc. | C17, c20, and c21 substituted neuroactive steroids and their methods of use |
| US20190233465A1 (en) | 2016-07-11 | 2019-08-01 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
| TW202342058A (zh) * | 2017-09-07 | 2023-11-01 | 美商賽吉醫療公司 | 神經活性類固醇及其使用方法 |
| US10562930B1 (en) * | 2018-08-31 | 2020-02-18 | Praxis Precision Medicines, Inc. | Salts and crystal forms of GABAA positive allosteric modulator |
| AU2019406803A1 (en) * | 2018-12-17 | 2021-07-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US20220125803A1 (en) * | 2019-03-04 | 2022-04-28 | Praxis Precision Medicines, Inc. | Methods for the treatment of perimenopause and menopause |
| MX2021014515A (es) | 2019-05-31 | 2022-03-22 | Sage Therapeutics Inc | Esteroides neuroactivos y composiciones de estos. |
| AU2020358002A1 (en) * | 2019-10-02 | 2022-04-21 | Praxis Precision Medicines, Inc. | Combinations of GABA-A receptor positive allosteric modulators and NMDA antagonists, NMDA negative allosteric modulators or NMDA partial agonists |
| WO2021168106A1 (en) * | 2020-02-18 | 2021-08-26 | Praxis Precision Medicines, Inc. | Deuterated neurosteroid |
| WO2022177718A1 (en) | 2021-02-18 | 2022-08-25 | Sage Therapeutics, Inc. | Use of neuroactive steroid for treatment of sexual dysfunction |
| JP2024506942A (ja) | 2021-02-18 | 2024-02-15 | プラクシス プレシジョン メディシンズ， インコーポレイテッド | Ｇａｂａ－ａポジティブアロステリック調節物質のヘミ－クエン酸塩およびその結晶形態 |
| CN117715641A (zh) * | 2021-04-26 | 2024-03-15 | 普拉西斯精密医药公司 | 用神经活性类固醇进行治疗的方法 |
| WO2023159035A1 (en) | 2022-02-16 | 2023-08-24 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of cns-related disorders |
| WO2023159094A2 (en) * | 2022-02-16 | 2023-08-24 | Praxis Precision Medicines, Inc. | PROCESS OF MAKING 3α-HYDROXY-3β-METHOXYMETHYL-21-(1'- IMIDAZOLYL)-5α-PREGNAN-20-ONE |
| WO2023164386A1 (en) * | 2022-02-28 | 2023-08-31 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of gastrointestinal diseases or conditions |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2535202B1 (fr) * | 1982-11-03 | 1985-08-09 | Fabre Sa Pierre | Comprimes de theophylline a liberation controlee et leur procede de fabrication |
| US4861598A (en) * | 1986-07-18 | 1989-08-29 | Euroceltique, S.A. | Controlled release bases for pharmaceuticals |
| GB8626098D0 (en) | 1986-10-31 | 1986-12-03 | Euro Celtique Sa | Controlled release hydromorphone composition |
| US4884909A (en) | 1986-12-25 | 1989-12-05 | Canon Kabushiki Kaisha | Recording apparatus |
| US5939545A (en) | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
| ATE195654T1 (de) * | 1994-02-14 | 2000-09-15 | Euro Celtique Sa | Androstane und pregnane zur allosterischen modulation des gaba-rezeptors |
| US5478572A (en) * | 1994-09-06 | 1995-12-26 | Bristol-Myers Squibb Co. | Gepirone dosage form |
| US5965161A (en) * | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
| US7083808B2 (en) * | 1998-12-17 | 2006-08-01 | Euro-Celtique S.A. | Controlled/modified release oral methylphenidate formulations |
| CZ20013867A3 (cs) * | 1999-04-29 | 2002-07-17 | Purdue Pharma Ltd. | 3alfa-hydroxy-3beta-methoxymethyl-21-heterocyklem substituované steroidy s anestetickým účinkem |
| US6387403B1 (en) * | 1999-09-15 | 2002-05-14 | Alza Corporation | Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing |
| US6080736A (en) * | 1999-10-27 | 2000-06-27 | Janus Pharmaceuticals, Inc. | Methods and compositions for treating and preventing anxiety and anxiety disorders using optically pure (R) tofisopam |
| GB0218876D0 (en) * | 2002-08-13 | 2002-09-25 | Merck Sharp & Dohme | Therapeutic agents |
| US20060074059A1 (en) * | 2004-08-26 | 2006-04-06 | Goliber Philip A | Isomorphic crystalline habits of 3alpha-hydroxy-21-(1'-imidazolyl)-3beta-methoxymethyl-5alpha-pregnane-20-one |
-
2006
- 2006-06-09 PL PL10000305T patent/PL2168585T3/pl unknown
- 2006-06-09 RS RS20120109A patent/RS52199B/en unknown
- 2006-06-09 DK DK06754274.6T patent/DK1888080T3/da active
- 2006-06-09 EP EP06754274A patent/EP1888080B1/en active Active
- 2006-06-09 CN CNA2006800200317A patent/CN101193640A/zh active Pending
- 2006-06-09 EA EA200800007A patent/EA013744B1/ru not_active IP Right Cessation
- 2006-06-09 WO PCT/EP2006/005574 patent/WO2006131392A1/en active Application Filing
- 2006-06-09 UA UAA200800334A patent/UA94909C2/ru unknown
- 2006-06-09 AT AT10000305T patent/ATE538797T1/de active
- 2006-06-09 EP EP10010923A patent/EP2263675A3/en not_active Withdrawn
- 2006-06-09 AT AT06754274T patent/ATE464054T1/de active
- 2006-06-09 RS RSP-2010/0265A patent/RS51304B/sr unknown
- 2006-06-09 CA CA2611430A patent/CA2611430C/en not_active Expired - Fee Related
- 2006-06-09 JP JP2008515150A patent/JP2008542419A/ja active Pending
- 2006-06-09 ES ES06754274T patent/ES2344313T3/es active Active
- 2006-06-09 PT PT10000305T patent/PT2168585E/pt unknown
- 2006-06-09 SI SI200631289T patent/SI2168585T1/sl unknown
- 2006-06-09 AU AU2006256851A patent/AU2006256851C1/en not_active Ceased
- 2006-06-09 US US11/921,889 patent/US20090131383A1/en not_active Abandoned
- 2006-06-09 PT PT06754274T patent/PT1888080E/pt unknown
- 2006-06-09 DK DK10000305.2T patent/DK2168585T3/da active
- 2006-06-09 EP EP10000305A patent/EP2168585B1/en active Active
- 2006-06-09 NZ NZ562979A patent/NZ562979A/en not_active IP Right Cessation
- 2006-06-09 KR KR1020087000520A patent/KR20080017091A/ko active Search and Examination
- 2006-06-09 KR KR1020107018375A patent/KR20100095661A/ko not_active Application Discontinuation
- 2006-06-09 SI SI200630698T patent/SI1888080T1/sl unknown
- 2006-06-09 BR BRPI0612921-8A patent/BRPI0612921A2/pt not_active IP Right Cessation
- 2006-06-09 ES ES10000305T patent/ES2380060T3/es active Active
- 2006-06-09 KR KR1020127005147A patent/KR20120028407A/ko not_active Application Discontinuation
- 2006-06-09 PL PL06754274T patent/PL1888080T3/pl unknown
- 2006-06-09 DE DE602006013622T patent/DE602006013622D1/de active Active
-
2007
- 2007-10-25 ZA ZA200709188A patent/ZA200709188B/xx unknown
- 2007-12-02 IL IL187813A patent/IL187813A/en not_active IP Right Cessation
- 2007-12-07 NO NO20076319A patent/NO20076319L/no not_active Application Discontinuation
-
2008
- 2008-08-18 HK HK08109178.7A patent/HK1118202A1/xx not_active IP Right Cessation
- 2008-08-18 HK HK10107380.1A patent/HK1140947A1/xx not_active IP Right Cessation
-
2010
- 2010-07-02 HR HR20100372T patent/HRP20100372T1/hr unknown
- 2010-07-09 CY CY20101100642T patent/CY1110199T1/el unknown
-
2011
- 2011-02-08 IL IL211114A patent/IL211114A/en not_active IP Right Cessation
- 2011-11-07 IL IL216194A patent/IL216194A/en not_active IP Right Cessation
-
2012
- 2012-03-21 CY CY20121100298T patent/CY1112499T1/el unknown
- 2012-03-23 HR HR20120264T patent/HRP20120264T1/hr unknown
- 2012-05-04 US US13/464,369 patent/US20120276196A1/en not_active Abandoned
- 2012-07-23 JP JP2012162303A patent/JP2012229261A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100372T1 (hr) | Farmaceutski sastavi neuroaktivnog steroida i njihova uporaba | |
| WO2007000778A3 (en) | Modified release pharmaceutical compositions on the basis of two polymers and processes thereof | |
| BRPI0406996A (pt) | Formas de dosagem sólida via transmucosa oral sem açúcar e sua utilização | |
| HK1126394A1 (en) | Solid oral pharmaceutical compositions for once daily dosing containing pregabalin, a matrix forming agent and a swelling agent | |
| ES2351947T3 (es) | Formulaciones orales de liberacion controlada de un inhibidor de la enzima convertidora de interleucina-1-beta. | |
| WO2008014175A3 (en) | Granular pharmaceutical compositions | |
| WO2008019996A3 (en) | Formulations of flibanserin and method for manufacturing the same | |
| EA200700049A1 (ru) | Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением | |
| IL180943A0 (en) | Multiparticle pharmaceutical dosage form for a low-soluble active substances and method for producing said pharmaceutical dosage form | |
| RS54329B1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING RIFAXIMINE, PROCEDURES FOR THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF VAGINAL INFECTIONS | |
| UA116334C2 (uk) | Тверді форми дозування бендамустину | |
| WO2007017331A3 (en) | Immediate release therapeutic systems for improved oral absorption of 7- [ (e) -tert-butyloxyiminomethyl] camptothecin | |
| WO2007025182A3 (en) | Drug compositions containing controlled release hypromellose matrices | |
| BR0013719A (pt) | Dosagem oral de liberaçâo controlada, apropriada para administração oral | |
| WO2008062475A3 (en) | Pharmaceutical compositions of ursodiol | |
| ATE491447T1 (de) | Flavonoide und tocotrienole enthaltende zusammensetzungen und deren verwendungen | |
| BRPI0412364A (pt) | composição farmacêutica sólida, compreendendo amisulpride | |
| WO2008027340A3 (en) | Topical ophthalmic formulations | |
| MXPA06007511A (es) | Revestimientos de granulos de farmaco que imparten resistencia a la embarradura durante la compresion mecanica. | |
| AR074689A1 (es) | Formulaciones farmaceuticas de desintegracion rapida pre-compactadas de compuestos con baja biodisponibilidad oral. proceso de preparacion | |
| PT1499278E (pt) | Forma de dosagem farmaceutica de libertacao imediata compreendendo tibolona polimorfa | |
| ZA200705660B (en) | Pharmaceutical polymer composition for oral controlled-release delivery of terbutaline sulfate | |
| WO2007119249A3 (en) | Pharmaceutical compositions of cefixime | |
| JO2440B1 (en) | Formulation of oral pharmaceutical polymers for controlled release of terbutalate sulfate. |